January 27, 2023 08:30 AM ESTUpdated February 7, 09:29 AM

#JPM23: BeiGene CEO John Oyler on the com­pa­ny's big am­bi­tions

Drew Armstrong

Executive Editor

BeiGene CEO John Oyler and End­points News Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one-on-one about where the drug­mak­er is head­ed in its quest to be­come a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times